WO2000057818A1 - Prothese endovasculaire a pelliculage integre destinee a etre deployee dans le corps - Google Patents

Prothese endovasculaire a pelliculage integre destinee a etre deployee dans le corps Download PDF

Info

Publication number
WO2000057818A1
WO2000057818A1 PCT/US2000/008757 US0008757W WO0057818A1 WO 2000057818 A1 WO2000057818 A1 WO 2000057818A1 US 0008757 W US0008757 W US 0008757W WO 0057818 A1 WO0057818 A1 WO 0057818A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
coating
tubular body
interior
film
Prior art date
Application number
PCT/US2000/008757
Other languages
English (en)
Inventor
Olexander Hnojewyj
Gregory M. Cruise
Stuart D. Edwards
Original Assignee
Cardio Synopsis Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio Synopsis Inc. filed Critical Cardio Synopsis Inc.
Priority to AU40633/00A priority Critical patent/AU4063300A/en
Publication of WO2000057818A1 publication Critical patent/WO2000057818A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063—Three-dimensional shapes
    • A61F2230/0073—Quadric-shaped
    • A61F2230/0078—Quadric-shaped hyperboloidal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Definitions

  • the invention relates to coatings for stents or grafts deployed in vessels or other lumens in the body.
  • Expandable stents are widely used throughout the body, e.g., in the heart, in the circulatory systems, in the gastro-intestinal tract, or in the urological tract.
  • Stents are used to hold open a segment of a blood vessel, an artery, or other body lumen.
  • expandable stents are commonly used to support and hold open a coronary artery after an angioplasty procedure.
  • expandable stents are made from a metal alloy, e.g., stainless steel.
  • the stents have a hollow tubular shape with a coiled, wound, or braided outer wall presenting an open lattice configuration.
  • the open lattice configuration imparts flexibility and the ability to expand in situ within a blood vessel or other body lumen.
  • the outer wall when used in the coronary artery, the outer wall is forced to expand in situ by an interior balloon into an enlarged shape.
  • These stents are called balloon-expandable stents.
  • the outer wall when used in larger peripheral blood vessels, the outer wall is biased or coiled toward a normally expanded condition, which can be compressed within a catheter tube to a smaller diameter for introduction.
  • These stents self expand into a larger diameter in situ within a blood vessel. These stents are called self-expanding stents .
  • stents possess an open mesh structure, which imparts flexibility and expansion capabilities.
  • the open mesh structure provides pathways for intimal hyperplasia into the interior of the stent.
  • Cellular ingrowth can, in time, contribute to a narrowing of the lumen diameter.
  • the stent comprises a tubular body having a lattice structure with open interstices.
  • the body includes an interior and an exterior.
  • the stent includes a biocompatible coating, which is applied to the tubular body as a flowable polymer.
  • the coating comprises a continuous film that envelops the entire lattice structure and spans the interstices of the lattice structure.
  • the film extends continuously between the interior and exterior of the stent and is free of an interior boundary layer.
  • the continuous polymeric film blocks or impedes cellular ingrowth.
  • the continuous polymeric film also possesses flexible and durable mechanical properties, which resist tearing or adhesion failure during normal flexure, expansion, or contraction of the enveloped tubular body.
  • the continuous polymeric film comprises an integral skin, which continuously conforms to the shape of tubular body, without failure or rupture.
  • the polymer of the coating comprises an elastomer material.
  • the polymer of the coating comprises a polyurethane material, and, most preferably, a polyether urethane urea material.
  • the coating carries a therapeutic agent.
  • the tubular body carries a microporous material that carries a therapeutic agent.
  • Fig. 1 is a perspective view of an expandable stent having a tubular body with open interstices
  • Fig. 2 is a perspective view of the stent shown in Fig. 1 after application of a biocompatible coating in accordance with the invention, which was applied to the tubular body as a flowable polymer;
  • Fig. 3 is an enlarged view of the coating applied to the stent shown in Fig. 2, showing the coating comprising a continuous film that envelops the entire lattice structure and spans the interstices of the lattice structure, extending continuously between the interior and exterior of the stent and being free of an interior boundary layer;
  • Fig. 4 is a side view of a mandrel usable to form the coating on the stent shown in Fig. 2, the mandrel being shown as a three part assembly in a disassembled condition;
  • Fig. 5 is a side view of the mandrel shown in Fig. 4 in a fully assembled condition
  • Fig. 6 is a side view of the mandrel shown in Fig. 4, partially assembled and receiving a stent for coating;
  • Fig. 7 is a side view of the mandrel shown in Fig. 4, fully assembled and holding a stent for coating;
  • Fig. 8 is an elevation view of the fully assembled mandrel shown in Fig. 7, being dipped into a solution of polymer material to apply the material to the stent;
  • Fig. 9 is an elevation view of the fully assembled mandrel shown in Fig. 7, placed in an oven for curing;
  • Fig. 10 is a side view of the mandrel shown in Fig. 7, disassembled to allow soaking of the coating to swell the polymer
  • Fig. 11 is a side view of the mandrel shown in Fig. 7 during the removal of the stent after the polymer has been swelled;
  • Fig. 12 is a side view of another seamless mandrel usable to form the coating on the stent shown in Fig. 2;
  • Fig. 13 is a perspective view of the stent shown in Fig. 2 after the incorporation of a drug or therapeutic agent in the biocompatible coating;
  • Fig. 14 is a perspective view of the stent shown in Fig. 2 with a microporous material having a drug or therapeutic agent wrapped about the biocompatible coating.
  • Fig. 2 shows an expandable stent 10 that embodies features of the invention.
  • the stent 10 may be either temporarily or permanently deployed in a body lumen, such as a coronary artery, carotid artery, vessels in the brain, aorta, peripheral arteries and veins, and the like.
  • the stent 10 can also be deployed in the urethra, esophagus, and other lumens throughout the body.
  • the stent 10 is used primarily to support the interior of the body lumen so that it remains patent and permits the uninterrupted flow of blood or other fluids through it.
  • the stent 10 includes a tubular body 12 (see Fig. 1).
  • the tubular body 12 is made, e.g., from plastic or metal or metal alloys such as stainless steel, tantalum, nickel-titanium, platinum/iridium, and a cobalt alloy.
  • the stent 10 includes an interior 14 and an exterior 16.
  • the tubular body 12 possesses an open lattice structure 17 of interwoven or braided wires, or struts, or coils.
  • the tubular body 12 is made this way by known etching processes or by laser cutting a metal tube, or by winding or weaving or braiding metal wires.
  • the open lattice structure imparts to the body 12 flexibility and the ability to expand from a small diameter and an enlarged diameter.
  • the tubular body 12 can be expanded in situ in various ways.
  • the body 12 can, e.g., be normally contacted and mounted in conventional fashion in a normally contracted state about a balloon dilation catheter. Expansion of the balloon expands the tubular body 12 for use within a lumen.
  • These stents called balloon-expandable stents, are commercially available from, e.g., Guidant Corporation (Santa Clara, California) ; Pal az-Shatz (Johnson and Johnson) , and Gianturco (Cook Incorporated) . Typically, these stents present a constricted diameter of about 2 mm and an enlarged diameter of about 5 mm.
  • the tubular body 12 can be braded or coiled to normally possess an expanded condition.
  • These stents are forced to a contracted state within a catheter tube for introduction. When released from the catheter tube, the stents self expand within the vessel or lumen.
  • These stents called self-expanding stents, are available from, e.g., Schneider (sold under the trade name WALLSTENTTM) , InStent (sold under the trade name CARDIOCOILTM) , and Cordis Corporation (sold under the trade name SmartStentTM) .
  • these stents present a constricted diameter of about 2 mm and an enlarged diameter of about 8 mm.
  • Fig. 2 shows the stent 10 shown in Fig. 1 after having been encapsulated within an inert, biocompatible coating 18 in accordance with the invention.
  • the coating 18 comprises a film 20 (see Fig. 3) that is applied to the tubular body 12 as a flowable polymer, as will be described in greater detail later.
  • the polymer undergoes a phase change to form the film 20.
  • the film 20 envelops the entire lattice structure 17 , spanning the interstices of the lattice structure 17.
  • the film 20 extends continuously between the interior 14 and exterior 16 of the stent 10 and is free of an interior boundary layer.
  • the tubular body 12 and continuous, boundary-free film 20 form an integrated structure along both interior 14 and exterior 16.
  • the film 20 possesses superior mechanical properties. During normal flexure, expansion, or contraction of the underlying tubular body 12, the film 20 continuously conforms to the shape of tubular body 12 , without rupture and without adhesion failure. Encapsulated in the film 20, the tubular body 12 takes on enhanced physical properties in terms of its biocompatibility, flexure, and durability.
  • the film 20 provides a uninterrupted, integral skin, which encapsulates the tubular body 12 within an inert, biocompatible envelope. The film 20 shields the tubular body 12 from contact with body fluids or tissue.
  • the coating 18 comprises a segmented polyurethane polymer material having a theoretical (i.e., calculated) molecular weight of about 70,000 g/mole to about 85,000 g/mole.
  • the polymer material possesses a linear structure imparting flexibility and durability.
  • the polymer material of the coating 18 is applied to the body 12 as a solution, e.g., by dipping or spraying.
  • the material of the coating 18 is most preferably formed from an aromatic polyether urethane urea, with a soft segment of polytetramethylene ether glycol (PTMEG) and a hard segment of diphenylmethane diisocyanate (MDI) and mixed diamines.
  • PTMEG polytetramethylene ether glycol
  • MDI diphenylmethane diisocyanate
  • the material preferably possesses a theoretical molecular weight between about 65,000 g/mole and about 100,000 g/mole, more preferably between 65,000 and 85,000 g/mole, and most preferably between 70,000 g/mole and 80,000 g/mole.
  • the material of the coating 18 also includes a stabilizing additive package consisting of an antioxidant and a surface modifying agent.
  • the material of the coating 18 has been demonstrated to be biocompatible and non-toxic in a variety of physiological applications.
  • the coating material is made in solution form in a three step reaction process.
  • PTMEG and MDI are reacted under controlled conditions within a reactor to form an isocynate prepolymer.
  • the isocynate prepolymer is next reacted with an amine package, which includes at least one agent to expand the prepolymer chain and at least one agent to stop the expansion of the prepolymer chain when a desired theoretical molecular weight is approached.
  • a stabilizer package is then added to the expanded polymer chain.
  • Solvent is added at each step of the process to maintain a desired viscosity to aid mixing and processing.
  • the result is a solution, which can be applied by dip coating, or roller coating, or spray coating to the stent, and which, when heat cured, forms the coating 18 having the desirable properties mentioned.
  • the prepolymer material includes between about 83 to 85 about percent (by solids weight) of a polytetramethylene ether glycol material (PTMEG) having a theoretical molecular weight of between about 1950 and 2050.
  • PTMEG polytetramethylene ether glycol material
  • the prepolymer also includes from about 14 to about 17 percent (by solids weight) of a 4,4'- Methylene bis (phenyl isocyanate) material (MDI) .
  • MDI is generally expressed as compounds of the formula:
  • the reaction of PTMEG and MDI is achieved by mixing in a heated reaction chamber, e.g., in a five gallon reactor, such as PflaudlerJ, Pflaudler RXJ, BNKOJ, or equivalent.
  • DMAC N,N-dimethylacetamide
  • the mixing yields a solution comprising a linear, isocyanate- terminated prepolymer.
  • the reaction and resulting polymer can be expressed as compounds of the formula:
  • the linear, isocyanate- terminated prepolymer solution preferably contains about 17% PTMEG, about 3% MDI, and about 80% DMAC.
  • the isocyanate-terminated prepolymer in the solution is next expanded by reaction with an amine package .
  • the amine package includes difunctional chain extenders, to cause expansion of the prepolymer chain.
  • the amine package also includes a chain stopper, to prevent the chain expansion beyond a desired magnitude, which would interfere with the physical properties desired for the coating.
  • the magnitude of expansion is selected to yield a desired theoretical molecular weight for the coating material, at which the desired durability and flexibility characteristics are achieved.
  • the magnitude of expansion is empirically determined, based upon the polymer materials used and other processing variables. In the preferred embodiment, the magnitude of expansion is about fifteen fold.
  • the amine package includes ethylene diamine (ETD) having a theoretical molecular weight of about 60.
  • ETD is a difunctional chain extender, which can be generally expressed as compounds of the formula:
  • DCH i s di aminocyc l ohexane having a theore t i cal molecular weight of about 114 .
  • DCH i s also a difunctional chain extender , which can be expressed as compounds of the formula :
  • the amine package further includes diethylamine (DEA) having a theoretical molecular weight of about 73.
  • DEA is a chain stopper, which 8
  • the amine package is mixed with the linear, isocyanate-terminated prepolymer solution under heat in the reactor. Solvent DMAC is also added to maintain desired processing viscosity.
  • a fifteen fold chain extension of the prepolymer is targeted.
  • the chain extension mixture (by solids weight percent) is prepolymer (98.1%); ETD (.57%); DCH (1.1%); and DEA (0.2%).
  • ETD .57%)
  • DCH .1%
  • DEA 0.2%)
  • the coating material includes a stabilizer package .
  • the stabilizer package includes an antioxidant 4, 4 ' -butylidene bis (6-tert-butyl-m-cresol) , which can be expressed as compounds of the formula:
  • the stabilizer package also includes a surface modifying (acrylic resin dispersion used as antisnag and bodying agents) additive co-diisopropylamino-ethylmethacrylate/decyl methacrylate, which can be expressed as compounds of the formula : o II
  • the stabilizer package is mixed with the extended prepolymer-amine solution under heat in the reactor.
  • Solvent DMAC is also added to maintain desired processing viscosity.
  • the coating material includes about 1% by solids weight of 4, 4'- butylidene bis (6-tert-butyl-m-cresol) and about 5% by solids weight of co-diisopropylamino- ethylmethacrylate/decyl methacrylate.
  • about 60 grams of DMAC is added for every 2042 grams of total solids.
  • Example 1 presents an illustrative example of the details of the making of the preferred coating material.
  • Empirical experience indicates that under the processing conditions of the
  • Example 2 the calculated 4.01 batch grams for the DEA chain stopper is not sufficient to stop the chain expansion at 15 fold. Based upon this empirical experience, the batch amount of DEA is doubled to 8.02 grams to provide a processing margin of error.
  • the amine package added to the 2000 grams of prepolymer is therefore composed of the following:
  • the amine package is added by drip funnel at 602C over a period of 15 minutes .
  • the prepolymer-amine mixture is stirred at 30 RPM's for 30 minutes at 60sc.
  • the temperature is lowered to 50 ⁇ C, the speed of mixing is reduced to 20 RPM's, and mixing under these conditions proceeds for an additional 30 minutes.
  • the polyether urethane urea material of the coating prepared according to the preceding Example (in shorthand called PEUU) can be applied while in a flowable solution state to a balloon-expandable stent or a self-expanding stent, to form the continuous film 20.
  • a seamless mandrel 22 (see Figs. 4 and 5) holds the stent while the material is applied.
  • the mandrel 22 is made, e.g., from stainless steel.
  • the mandrel 22 can be variously constructed.
  • the mandrel 22 comprises three separable pieces; namely, a front piece 24, a handle piece 26, and an intermediate stent mount 28.
  • the front piece 24 includes an enlarged grip having a diameter D2 greater than the diameter Dl of the stent mount 28.
  • the front piece 24 includes a tapered neck 30.
  • the front piece 24 progressively diminishes in diameter along the neck 30 from the grip diameter D2 to a stem 32.
  • the stem 32 extends a short distance beyond the tapered neck 30.
  • the stem 32 has a diameter egual to the mount diameter Dl.
  • a circumferential groove 34 is formed on the tapered neck 30 in advance of the stem 32.
  • a centered, stepped bore 36 passes through the front piece 24 to accommodate insertion of a shoulder bolt 38.
  • the externally threaded end 40 of the shoulder bolt 38 extends beyond the stem 32 to engage an internally threaded, centered, stepped bore 42 in the stent mount 28.
  • the shoulder bolt 38 threads into the bore 42 to connect the front piece 24 to the stent mount 28.
  • a witness line 44 marks the abutment of the stem 32 and an end of the stent mount 28. Due to the stem 32, the witness line 44 is spaced inward of the tapered neck 30 and groove 34. The witness line 44 is machined smooth, to present a seamless junction.
  • the handle piece 26 is longer than the front piece 24, to provide more gripping area for manipulating the mandrel 22 during use.
  • the handle piece 26 includes an enlarged grip having a diameter D3 greater than the diameter Dl of the stent mount 28.
  • the handle piece 26 also includes a tapered neck 46, along which the handle piece 26 progressively diminishes in diameter from the grip diameter D2 to a stem 48.
  • the stem 48 also extends a short distance beyond the tapered neck 46.
  • the stem 48 has a diameter equal to the mount diameter Dl.
  • Another circumferential groove 50 is formed on the tapered neck 46 in advance of the stem 48.
  • a centered, stepped bore 52 passes through the handle piece 26 to accommodate insertion of a second shoulder bolt 54.
  • the externally threaded end 56 of the second shoulder bolt 54 extends beyond the stem 48 to engage the internally threaded, centered stepped bore 58 in the stent mount 28.
  • the shoulder bolt 54 threads into the bore 58 to connects the handle piece 26 to the stent mount 28.
  • a second witness line 60 marks the abutment of the stem 48 and the stent mount 28. Like the first witness line 44, the second witness line is spaced inward of the tapered neck 46 and groove 50.
  • the witness line 44 is likewise machined smooth, to present another seamless junction.
  • the technician connects the handle piece 26 to the stent mount 28.
  • the technician slides the stent S to be coated onto the stent mount 28.
  • the technician slides a balloon-expandable stent onto the mount 28 in its normal constricted condition.
  • the technician slides a self-expanding stent on to the mount 28 in its fully expanded condition.
  • the difference in diameter between Dl and the interior diameter of the stent S, when placed on the mount 28, defines the thickness of the film 20 along the interior of the stent S.
  • the exterior surface of the mount 28 can be uniform or tapered or flouted to create non iso-radial or otherwise nonuniform regions.
  • the mount 28 could also be curved along its length to impart a bias.
  • the diameter Dl of the mount 28 exceeds the interior diameter of the stent S, when mounted for coating, by about 0.314 inches ⁇ 0.001 inches. This diameter difference provides a sufficient film thickness, while preventing "floating" of the stent S on the stent mount 28. Given this diameter difference, the stent stays in position and does not shift side-to-side along the stent mount 28 during coating.
  • the technician secures the front piece 24 to the mount 28 (see Fig. 7) .
  • the length of the mount 28 is selected to allow the ends of the stent S to extend a distance beyond the stems 32 and 48 and onto the tapered necks 30 and 46, but short of the grooves 34 and 50.
  • the front piece 24 and the handle 26 hold the stent S in slight compression on the stent mount 28, to assure that the interstices are held open during the coating process.
  • the mandrel 22 and stent S are dipped into a bath 62 containing a flowable solution 64 of PEUU (see Fig. 8) .
  • the bath 62 preferably includes a recirculation loop 66, to maintain mixing within the bath 62.
  • the recirculation loop 66 also preferably includes an in line filter 68 to remove congealed particles from the PEUU solution.
  • the recirculation loop 66 also preferably includes a viscosity sensor 70, to assure that solvent loss during processing does not lower the viscosity below a desired level.
  • the mandrel 22 and stent S are removed from the bath 62.
  • the excess PEUU solution 64 is allowed to drain off the stent S.
  • the mandrel 22 may be held by the handle piece 26 and rotated about its axis to aid in the drainage of PEUU solution 64.
  • a phase change is induced in the flowable polymer solution 64 by placing the stent S and mandrel
  • the mount 28 itself can be internally heated to flash the solvent.
  • the film 20 formed beyond the ends of the stent S are scored, using grooves 34 and 50 to guide the cutting.
  • the edges of the film 20 are teased back to break surface contact about the stems 32 and 48.
  • the shoulder bolts 38 and 54 are screwed loose, and the handle piece 26 and front pieces 24 are removed.
  • the coated stent S still carried by the mount 28, is placed in a dish of polymer swelling agent 106, e.g., isopropyl alcohol (10%) (see Fig. 10).
  • the agent 106 causes the film 20 to swell sufficient to slide the coated stent S from the mount 28 (see Fig. 11).
  • a typical stent has a wall thickness of about 0.081 inches.
  • a representative thickness for the coating is about 0.001 inches.
  • the seamless mandrel 22 comprises a two piece assembly, comprising a handle end 78 and the front end 80.
  • the handle end 78 includes a neck 82 which tapers to an elongated stem 84 having a stepped threaded end 86.
  • the front end 80 includes a neck 88 which tapers to an elongated stem 90 having an interior threaded bore 92.
  • the end 86 threads into the bore 92 to join the handle end 78 and front end 80.
  • the witness line 94 is machined smooth to create a seamless junction.
  • the elongated stems 84 and 90 form a stent mount 96. Score grooves 98 and 100 are formed in the tapered necks 82 and 88, respectively.
  • the stent S is placed on the handle piece 78, and the front piece 80 is threaded to the handle piece 78 to form the mandrel 22.
  • the coating process proceeds in the manner previously described
  • the process using a seamless mandrel 22 applies a biocompatible coating as a flowable polymer to the tubular body of the stent.
  • the flowable polymer undergoes a phase change to form a solid film that envelops the interior and exterior surfaces and occludes the interstices of the tubular body.
  • the film is continuous and free of boundary between the interior and exterior.
  • the continuous coating affects recoil either stent by no more than 5%.
  • a stent coated according to the invention can be used deployed throughout the body, e.g., in the nervous system, in the heart, in the circulatory systems, in the gastro-intestinal tract, or in the urological tract. D. Drug Delivery
  • the presence of the film 20 on the stent 10 also allows for the retention of a drug 102 and the dispensement of the drug 102 by the polymer of the film 20 (see Fig. 13) .
  • a microporous material 104 carrying the same or a different drug 102 can be further applied over the film 20 (see Fig. 14) .
  • an anticoagulant such as heparin or the like can be bound to the polymer and dispensed from the film 20 and/or the microporous material 104 in a time-released fashion after deployment, e.g., to reduce thrombosis.
  • other drugs such as anti-inflamatory agents, steroids, antimitotic drugs like che o- or radio-therapeutic drugs, or vascular endothelial growth factor (VEGF) or fibroblast growth factor (FGF) or other angiogenesis agents (promoting blood vessel growth) can be bound to the polymer of the film 20 and/or the microporous material 104 for release after deployment.
  • VEGF vascular endothelial growth factor
  • FGF fibroblast growth factor
  • angiogenesis agents promoting blood vessel growth
  • a stent coated according to the invention can be used as a drug delivery mechanism throughout the body, e.g., in the nervous system, in the heart, in the circulatory systems, in the gastro-intestinal tract, or in the urological tract.
  • the coated stents can incorporate angiogenesis agents, available, e.g., VEGF from Genetech or FGF from Chiron.
  • the coated stents can be deployed in one or more coronary arteries.
  • the coated stents release the angiogenesis agents over time.
  • the angiogenesis agents promote the growth of new capillaries in the heart.
  • the new capillaries restore the link between the arteries and veins residing in previously blood starved regions of heart muscle, thereby obviating the need for tradition bypass surgery or angioplasty.

Abstract

L'invention concerne une prothèse endovasculaire (10) extensible, destinée à être déployée dans le corps et constituée d'un corps (12) tubulaire doté d'une partie intérieure (14), d'une partie extérieure (16) et d'une structure maillée (17) comprenant des interstices ouverts. La prothèse endovasculaire est recouverte d'une pellicule (18) biocompatible qui est appliquée sur le corps tubulaire comme un polymère fluide. La pellicule est formée d'un film (20) continu qui enveloppe entièrement la structure maillée et couvre les interstices de la structure maillée. Le film s'étend en continu entre l'intérieur et l'extérieur de la prothèse endovasculaire et ne comporte pas de couche limite intérieure.
PCT/US2000/008757 1999-03-29 2000-03-29 Prothese endovasculaire a pelliculage integre destinee a etre deployee dans le corps WO2000057818A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40633/00A AU4063300A (en) 1999-03-29 2000-03-29 Stent with an integrated film coating for deployment throughout the body

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28016199A 1999-03-29 1999-03-29
US09/280,161 1999-03-29

Publications (1)

Publication Number Publication Date
WO2000057818A1 true WO2000057818A1 (fr) 2000-10-05

Family

ID=23071944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008757 WO2000057818A1 (fr) 1999-03-29 2000-03-29 Prothese endovasculaire a pelliculage integre destinee a etre deployee dans le corps

Country Status (2)

Country Link
AU (1) AU4063300A (fr)
WO (1) WO2000057818A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052772A1 (fr) * 2000-01-19 2001-07-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health_Human Servicesthe National Institutes Of Health Procede et appareil de revetement d'une endoprothese
EP1262153A1 (fr) * 2001-05-31 2002-12-04 Centrafid S.A. Stent pour vaisseaux vasculaites
US6503556B2 (en) 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6540776B2 (en) 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
WO2003105729A1 (fr) * 2002-06-13 2003-12-24 Henry Israel Endoprothese revetue par greffage, et procede d'elaboration correspondant
WO2004028579A2 (fr) * 2002-09-27 2004-04-08 Labcoat Ltd. Revetement de contact pour protheses
WO2004064894A3 (fr) * 2003-01-15 2005-06-09 Scimed Life Systems Inc Catheter, drain et stent textiles a placement intraluminal
EP1779816A3 (fr) * 2005-11-01 2007-05-23 Nitinol Development Corporation Extenseur avec revêtement mince à elution de médicaments
US7572288B2 (en) 2001-07-20 2009-08-11 Microvention, Inc. Aneurysm treatment device and method of use
US8715312B2 (en) 2001-07-20 2014-05-06 Microvention, Inc. Aneurysm treatment device and method of use
US20140163445A1 (en) * 2011-08-05 2014-06-12 Materialise Nv Lattice structure made by additive manufacturing
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US9023094B2 (en) 2007-06-25 2015-05-05 Microvention, Inc. Self-expanding prosthesis
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US9622753B2 (en) 2001-07-20 2017-04-18 Microvention, Inc. Aneurysm treatment device and method of use
US10058330B2 (en) 2011-05-11 2018-08-28 Microvention, Inc. Device for occluding a lumen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4776337A (en) * 1985-11-07 1988-10-11 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4776337A (en) * 1985-11-07 1988-10-11 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4776337B1 (en) * 1985-11-07 2000-12-05 Cordis Corp Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052772A1 (fr) * 2000-01-19 2001-07-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health_Human Servicesthe National Institutes Of Health Procede et appareil de revetement d'une endoprothese
US6503556B2 (en) 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6540776B2 (en) 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
EP1262153A1 (fr) * 2001-05-31 2002-12-04 Centrafid S.A. Stent pour vaisseaux vasculaites
WO2002096319A2 (fr) * 2001-05-31 2002-12-05 Centrafid S.A. Tuteur endovasculaire
WO2002096319A3 (fr) * 2001-05-31 2004-04-22 Centrafid S A Tuteur endovasculaire
US8562667B2 (en) 2001-07-20 2013-10-22 Microvention, Inc. Aneurysm treatment device and method of use
US9622753B2 (en) 2001-07-20 2017-04-18 Microvention, Inc. Aneurysm treatment device and method of use
US9539122B2 (en) 2001-07-20 2017-01-10 Microvention, Inc. Aneurysm treatment device and method of use
US8715312B2 (en) 2001-07-20 2014-05-06 Microvention, Inc. Aneurysm treatment device and method of use
US7572288B2 (en) 2001-07-20 2009-08-11 Microvention, Inc. Aneurysm treatment device and method of use
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
WO2003105729A1 (fr) * 2002-06-13 2003-12-24 Henry Israel Endoprothese revetue par greffage, et procede d'elaboration correspondant
US9272307B2 (en) 2002-09-27 2016-03-01 Boston Scientific Scimed, Inc. Contact coating of prostheses
WO2004028579A3 (fr) * 2002-09-27 2004-07-01 Labcoat Ltd Revetement de contact pour protheses
WO2004028579A2 (fr) * 2002-09-27 2004-04-08 Labcoat Ltd. Revetement de contact pour protheses
WO2004064894A3 (fr) * 2003-01-15 2005-06-09 Scimed Life Systems Inc Catheter, drain et stent textiles a placement intraluminal
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
EP1779816A3 (fr) * 2005-11-01 2007-05-23 Nitinol Development Corporation Extenseur avec revêtement mince à elution de médicaments
US9023094B2 (en) 2007-06-25 2015-05-05 Microvention, Inc. Self-expanding prosthesis
US10058330B2 (en) 2011-05-11 2018-08-28 Microvention, Inc. Device for occluding a lumen
US20140163445A1 (en) * 2011-08-05 2014-06-12 Materialise Nv Lattice structure made by additive manufacturing

Also Published As

Publication number Publication date
AU4063300A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
WO2000057818A1 (fr) Prothese endovasculaire a pelliculage integre destinee a etre deployee dans le corps
US8882822B2 (en) Non-thrombogenic stent jacket
US6468300B1 (en) Stent covered heterologous tissue
JP4916615B2 (ja) 自己拡張性ステント移植片
US6010530A (en) Self-expanding endoluminal prosthesis
JP4916616B2 (ja) 自己拡張性ステント移植片を作成するための方法
JP2020114545A (ja) 医療用デバイス
US9056157B2 (en) Hybrid biodegradable/non-biodegradable stent, delivery system and method of treating a vascular condition
EP1729681B1 (fr) Stent partiellement biodegradable
US8025495B2 (en) Apparatus and method for making a spider occlusion device
EP2107895A1 (fr) Prothèse médicale et procédé de production
EP2344088B1 (fr) Procédé de revetement d'un stent
US20090125100A1 (en) Intraluminal Bypass Prosthesis and Prosthesis Delivery and Deployment Kit
CA2533339A1 (fr) Stent a mettre en place in vivo
WO2004060213A1 (fr) Stent hybride a liens polymeres
AU2005285454A1 (en) Covered stent with controlled therapeutic agent diffusion
KR20150082385A (ko) 증착된 지지 구조체에 관련된 장치 및 방법
WO2012115275A1 (fr) Prothèse vasculaire
US20090171454A1 (en) Coated stent and methods of manufacture
JP3989570B2 (ja) 循環器用被覆ステント及びその製造方法
WO2020031193A1 (fr) Ensemble endoprothèse - greffe
US20050021133A1 (en) Tubular stents sandwiched inside of a composite membrane and methods of making and using thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)